UPB today
$2.78-$0.08 (-2.80%)close Nov 13, 2026Trend
DailyDowntrend (confirmed)
4 hourStrong Bearish
1 hourStrong Bearish
15 minStrong Bearish
5 minStrong Bullish
Daily trend turns up above $5.56
Key levels
Resistance$5.56
Resistance$3.84
Support$2.68
Latest news & SEC filings
AnalystHC Wainwright keeps Buy rating on Upstream Bio, cuts price target to $18
EarningsUpstream Bio Posts Q3 2026 Financials
All UPB news →About Upstream Bio
Upstream Bio is a biotech firm focused on creating therapies for inflammatory conditions, starting with serious lung diseases. Its main candidate, verekitug, is an antibody designed to block the TSLP receptor and is under study for severe asthma, nasal polyps with chronic sinus inflammation, and COPD. The company is based in the United States and works with outside manufacturers and research partners.
Based on the company's 10-K filed Mar 26, 2026.
Nasdaq · Healthcare
Upstream Bio, Inc. (UPB)
What Is the Price Target for UPB?
SEPT Low Target
$9.00
SEPT Mid Target
$15.00
SEPT High Target
$36.00
Analyst Consensus
$15.00
Is UPB a Buy or Sell Right Now?
Thesis
- •Revenue growing 20.4% YoY with ACCELERATING trend — accelerating momentum.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for UPB.
Start Free Trial →Is UPB Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
P/B, Analyst Consensus
Fair Value
$14.46
27
Moat Score
NONE
2/9
Piotroski Score
5.8
Altman Z-Score
What Is Smart Money Doing with UPB?
Insider Signal
SELLING
0 buys / 7 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
MEDIUM
Signal: NEUTRAL
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| GRAY MICHAEL | officer | Sale | 853 | $5K | Sep 16, 2026 |
| Sutherland Everett Rand | director officer | Sale | 2,095 | $12K | Sep 16, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →UPB Growth Story
Revenue YoY
20.4%
3yr Revenue CAGR
N/A%
EPS Growth YoY
52.33%
FCF Growth YoY
-123.6%
Revenue Trend
ACCELERATING
Dark Pool Trades for UPB
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for UPB, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 15:10:49 | $2.78 | 1,300 | $$4K | MIDPOINT |
| 21:00:02 | $2.86 | 1,000 | $$3K | BUY |
| 21:00:00 | $2.86 | 1,661 | $$5K | SELL |
| 20:59:54 | $2.85 | 1,023 | $$3K | MIDPOINT |
| 20:59:51 | $2.85 | 3,813 | $$11K | MIDPOINT |
5 dark pool trades shown · $$25K preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for Upstream Bio, Inc. (UPB) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (0 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →UPB — frequently asked questions
What is UPB stock price today?
Upstream Bio, Inc. (UPB) is at $2.78, down 2.80% (-$0.08) at the Nov 13, 2026 close.
Why is UPB stock moving today?
Latest UPB news — Nov 11, 2026: HC Wainwright keeps Buy rating on Upstream Bio, cuts price target to $18 · Nov 10, 2026: Upstream Bio Posts Q3 2026 Financials
What is the UPB price target?
The average analyst price target for UPB is $15.00, ranging from $9 to $36, based on 5 analysts.
What do analysts rate UPB?
Analyst ratings for UPB: 0 Buy, 4 Hold, 3 Sell — consensus Hold.
Did UPB beat earnings?
UPB last reported on Aug 11, 2026: EPS -$0.73 vs -$0.78 expected — a beat of 6.4%.
Does UPB pay a dividend?
UPB does not currently pay a dividend.
What are UPB support and resistance levels?
Support: $2.68. Resistance: $3.84, $5.56, $6.09.
What are insiders doing with UPB?
Insider activity: SELLING, 0 buys and 7 sells in the last 90 days.
What is the latest news on UPB?
Nov 11, 2026: HC Wainwright keeps Buy rating on Upstream Bio, cuts price target to $18 · Nov 10, 2026: Upstream Bio Posts Q3 2026 Financials